Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
14-12-09	Merck : to take on superbugs with Cubist Pharma buy	RE
14-12-08	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
14-12-08	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
14-12-08	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
14-12-05	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
13-05-20	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

15-01-13	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
14-12-19	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
14-12-15	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company	PR
14-12-12	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
14-12-12	Cubist Pharmaceuticals : CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.	BU

14-12-21	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
14-12-20	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
14-12-09	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
14-12-08	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
14-12-08	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	1996-12-31

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	2006-08-31
Kenneth J. Martin BRD	Director/Board Member	72	2013-09-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+1.00%	+4.39%	+43.53%	-0.12%	80.48B
SAMSUNG BIOLOGICS CO.,LTD.	+0.97%	+3.30%	-2.19%	+26.99%	51.06B
UCB	-1.22%	-2.62%	+15.13%	+167.13%	48.19B
CSL LIMITED	-0.95%	+3.18%	-49.50%	-48.14%	46.5B
BIOGEN INC.	+0.85%	+2.12%	+55.82%	-23.03%	31.12B
MODERNA, INC.	-0.03%	+18.18%	+136.71%	-37.28%	25.41B
INCYTE CORPORATION	-0.21%	+1.81%	+40.38%	+82.80%	24.43B
INNOVENT BIOLOGICS, INC.	-1.31%	-1.00%	-2.19%	+189.81%	21.11B
BRIDGEBIO PHARMA, INC.	-3.14%	-1.92%	+61.19%	+161.38%	15.88B
Average	-0.43%	+3.44%	+33.21%	+57.73%	38.24B
Weighted average by Cap.	-0.07%	+3.12%	+25.98%	+41.00%